Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth B Hirsch

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Plos One|August 25, 2022
The antimicrobial peptide DGL13K is active against drug-resistant gram-negative bacteria and sub-inhibitory concentrations stimulate bacterial growth without causing resistanceSven-Ulrik Gorr, Hunter V Brigman, Jadyn C Anderson, et al.
Therapeutics and Clinical Risk Management|June 10, 2016
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsStephanie E Giancola, Monica V Mahoney, Tiffany E Bias, et al.
Diagnostic Microbiology and Infectious Disease|December 8, 2015
Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremiaTwisha S Patel, Jessica M Cottreau, Elizabeth B Hirsch, et al.
Open Forum Infectious Diseases|April 2, 2021
A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant <i>Pseudomonas aeruginosa</i> InfectionsDelaney E Hart, Jason C Gallagher, Laura A Puzniak, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|October 31, 2022
Opportunities for antibiotic stewardship in emergency department or hospitalized patients with asymptomatic bacteriuria: identifying risk factors for antibiotic treatmentMorgan L Bixby, Brian R Raux, Aakansha Bhalla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
Adding Antimicrobial Stewardship Pharmacists to the Infectious Diseases Compensation Discussion: A More Perfect Union?Keenan Levy Ryan, Meghan Jeffres, Krutika Mediwala Hornback, et al.
Plos One|August 6, 2016
The Activity of Antimicrobial Surfaces Varies by Testing Protocol UtilizedMatias D Campos, Paola C Zucchi, Ann Phung, et al.
Clinical and Translational Science|May 18, 2026
Prevotella bivia Influences Antiretroviral Pharmacokinetics and Viral Replication in an Ex Vivo Vaginal Tissue ModelAlyssa M Lantz, Lindsey B Collins, Elizabeth B Hirsch, et al.
Pharmacotherapy|February 24, 2023
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases PharmacistsEric Wenzler, Mira Maximos, Tomefa E Asempa, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 25, 2025
Evaluation of cefazolin <3 g vs. 3 g treatment doses for cellulitis in patients who weigh ≥120 kg within a large, community health system via modified desirability of outcomes ranking (DOOR) methodologyKrista D Gens, Brandon R Gagnon, Kimberly C Claeys, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Plos One|August 25, 2022
The antimicrobial peptide DGL13K is active against drug-resistant gram-negative bacteria and sub-inhibitory concentrations stimulate bacterial growth without causing resistanceSven-Ulrik Gorr, Hunter V Brigman, Jadyn C Anderson, et al.
Therapeutics and Clinical Risk Management|June 10, 2016
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsStephanie E Giancola, Monica V Mahoney, Tiffany E Bias, et al.
Diagnostic Microbiology and Infectious Disease|December 8, 2015
Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremiaTwisha S Patel, Jessica M Cottreau, Elizabeth B Hirsch, et al.
Open Forum Infectious Diseases|April 2, 2021
A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant <i>Pseudomonas aeruginosa</i> InfectionsDelaney E Hart, Jason C Gallagher, Laura A Puzniak, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|October 31, 2022
Opportunities for antibiotic stewardship in emergency department or hospitalized patients with asymptomatic bacteriuria: identifying risk factors for antibiotic treatmentMorgan L Bixby, Brian R Raux, Aakansha Bhalla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2023
Adding Antimicrobial Stewardship Pharmacists to the Infectious Diseases Compensation Discussion: A More Perfect Union?Keenan Levy Ryan, Meghan Jeffres, Krutika Mediwala Hornback, et al.
Plos One|August 6, 2016
The Activity of Antimicrobial Surfaces Varies by Testing Protocol UtilizedMatias D Campos, Paola C Zucchi, Ann Phung, et al.
Clinical and Translational Science|May 18, 2026
Prevotella bivia Influences Antiretroviral Pharmacokinetics and Viral Replication in an Ex Vivo Vaginal Tissue ModelAlyssa M Lantz, Lindsey B Collins, Elizabeth B Hirsch, et al.
Pharmacotherapy|February 24, 2023
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases PharmacistsEric Wenzler, Mira Maximos, Tomefa E Asempa, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|October 25, 2025
Evaluation of cefazolin <3 g vs. 3 g treatment doses for cellulitis in patients who weigh ≥120 kg within a large, community health system via modified desirability of outcomes ranking (DOOR) methodologyKrista D Gens, Brandon R Gagnon, Kimberly C Claeys, et al.
Pageof 8